AMARIN CORP PLC\UK

This Quarterly Report on Form 10-Q contains forward-looking information based on our current expectations. Because our actual results may differ materially from any forward-looking statements that we make or that are made on our behalf, this section includes a discussion of important factors that could affect our actual future results, including, but not limited to, our ability to successfully commercialize VASCEPA and VAZKEPA, collectively referred to as VASCEPA, our capital resources, the progress and timing of our clinical programs, the safety and efficacy of our product candidates, risks associated with regulatory filings, the potential clinical benefits and market potential of our product candidates, commercial market estimates, future development efforts, patent protection, effects of healthcare reform, reliance on third parties effects of tax reform, and other risks set forth below.

There have been no material changes to the risk factors presented under Item 1A. Risk Factorsin our Annual Report on Form 10-K for the year ended December 31, 2025. See Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2025 for a detailed discussion of risk factors affecting the Company.